The following research analysts periodically publish material commenting on Diurnal.  Please note that any opinions, estimates or forecasts regarding the Company's performance made by analysts are theirs alone and do not represent opinions, forecasts or predictions of the Company or its Management.  You should, therefore, not place undue reliance on the content of any such analyst report or statement and Diurnal accepts no responsibility for the views of these or any other analysts.

Company Analyst

Calvine Partners

Brian White

Hardman & Co

Martin Hall

Panmure Gordon

Mike Mitchell

The latest Calvine Partners reports are available on its website 

The latest Hardman & Co reports are available on its website

Report date Report name Report

13 Aug 2020

Flow of regulatory approvals

30 Mar 2020

$52.5m US deal strengthens balance sheet further

28 Feb 2020

...and more to come (news flow)

26 Nov 2019

Successful DITEST Phase I trial outcome

05 Nov 2019

Approaching a number of near-term milestones

25 Apr 2019

Clarity for Chronocort regulatory pathway

16 Jan 2019

Chronocort - seeking regulatory advice

18 Oct 2018

Unexpected Phase III trial outcome

04 Oct 2018

First commercial revenues

21 Mar 2018

Capital increase to support commercial plans

19 Dec 2017

Alkindi®: On route to Europe

14 Sep 2017

Ready to press the button

27 Mar 2017

Commercial and development progress

19 Jan 2017

Infacort on track to market

27 Oct 2016

Get the rhythm